
YET:
*". . . (W)hen it comes to a drug that is currently listed in schedule I, if it is undisputed that such drug has no currently accepted medical use
in treatment in the United States and a lack of accepted safety for use under medical supervision, and it is further undisputed that
the drug has at least some potential for abuse
sufficient to warrant control under the CSA, the drug must remain in
schedule I."
- March 20, 2001; Donnie R. Marshall, Administrator, U.S. Department of Justice,
Drug Enforcement Administration,
Washington, D.C.
**". . . (C)annabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults,
such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's
disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil(sic), are particularly advantageous to use
because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses . . ."
- October 7, 2003; United States Patent #6630507, originally filed April 21, 1999!
